ZAKA VC — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases.
BiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Olof Mollstedt(Founder)inHelen Chen(Founder)in
BoardSungwon Lim(Director)
Co-investorsY Combinator
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA.
BiotechDeep TechCambridge, US
Floris Engelhardt(Executive Officer, Director)John Vroom(Director)
BoardAnn DeWitt(Director)in
Co-investorsFifty YearsLaunchpad Venture GroupMetaplanetThe Engine VenturesVsquared Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.